Download useful resources and watch medical experts talk about FABHALTAView Resources

Ask your doctor about FABHALTA, a groundbreaking,  
FDA-approved oral PNH treatment for adults 

Improved hemoglobin (Hb) levels with the first FDA-approved oral treatment for adults with PNH. In a study of 62 people receiving FABHALTA and 35 people receiving C5 inhibitors, 82% of people taking FABHALTA had an increase in Hb ≥2 g/dL vs 0% of people taking C5 inhibitors (23 on SOLIRIS^® [eculizumab] and 12 on ULTOMIRIS^® [ravulizumab-cwvz]). 68% of people taking FABHALTA had Hb levels ≥12 g/dL vs 0% of people taking C5 inhibitors. These results were achieved in the absence of red blood cell transfusions after 24 weeks.

FABHALTA was studied in adults with PNH who had never been on a complement inhibitor before and in people who switched from C5 inhibitors. 

ULTOMIRIS^® (ravulizumab-cwvz) and SOLIRIS^® (eculizumab) are registered trademarks of Alexion Pharmaceuticals, Inc.